What is the difference between psoriatic arthritis and ankylosing spondylitis

PsA and AS are considered genetically and clinically related because both are inflammatory rheumatic diseases linked to the HLA-B27 gene. HLA-B27 is a powerful predisposing gene associated with several rheumatic diseases. The gene itself does not cause disease, but can make people more susceptible. The symptoms of PsA, which vary from person to person, can change in severity.

Skin symptoms typically but not always appear before the joints become involved, sometimes up to 10 years before. Without treatment, many of these symptoms can lead to progressive, permanent joint damage. Diagnosing psoriatic arthritis PsA can be tricky, primarily because it shares similar symptoms with other diseases such as osteoarthritis, rheumatoid arthritis, and gout.

Because of this, misdiagnosis can often be a problem. Early diagnosis, however, is important because long-term joint damage can be warded off better in the first few months after symptoms arise. The exact cause of psoriatic arthritis is not known, but it is known that heredity plays a large role. Up to 40 percent of people with PsA have a close relative with the disease. If an identical twin has PsA, there is a 75 percent chance that the other twin will have it as well.

Men and women are equally likely to develop psoriatic arthritis. PsA may strike at any age, but most commonly begins between the ages of 30 and In children who develop PsA, the most common age of onset is 11 to Disease course and prognosis vary from individual to individual, and also depend on the form the disease takes. For example, someone who is HLA-B27 positive is more likely to have the disease progress to involve the spine.

Also, the severity of the rash does not mirror the severity of the arthritis, and the skin condition does not necessarily occur at the same time as the arthritis. Although there is currently no known cure, there are treatments and medications available to reduce symptoms and manage the pain and inflammation caused by PsA. The most common medications for PsA are often also used to treat ankylosing spondylitis, including nonsteroidal anti-inflammatory drugs NSAIDs , disease-modifying antirheumatic drugs DMARDs , sulfasalazine Azulfidine , immunosuppressants, and biologic medications, such as TNF inhibitors.

Exercise is essential for preserving strength and maintaining range of motion in patients with PsA. Moghaddassi, M. Different aspects of psoriasis: analysis of Iranian patients.

Coates, L. Sensitivity and specificity of the classification of psoriatic arthritis criteria in early psoriatic arthritis.

Niccoli, L. Frequency of iridocyclitis in patients with early psoriatic arthritis: a prospective, follow up study. Nossent, J. Epidemiological and clinical characteristics of psoriatic arthritis in northern Norway. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Axial psoriatic arthritis: update on a longterm prospective study. Hanly, J. Psoriatic spondyloarthropathy: a long term prospective study. Queiro, R. Clinically asymptomatic axial disease in psoriatic spondyloarthropathy.

A retrospective study. Differences in the expression of spondyloarthropathy: a comparison between ankylosing spondylitis and psoriatic arthritis. Lubrano, E. The definition and measurement of axial psoriatic arthritis. Axial psoriatic arthritis: an intriguing clinical entity or a subset of an intriguing disease?

Jadon, D. Axial disease in psoriatic arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis. Exarchou, S. The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register study. Arthritis Res. Cortes, A. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci.

Ankylosing spondylitis: beyond genome-wide association studies. Brown, M. Genetics of ankylosing spondylitis — insights into pathogenesis.

Wordsworth, P. Genes in the spondyloarthropathies. North Am. Uddin, M. Integrated genomics identifies convergence of ankylosing spondylitis with global immune mediated disease pathways. Essers, I. Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: year results from OASIS. Rheumatology 54 , — Machado, P.

Ankylosing spondylitis patients with and without psoriasis do not differ in disease phenotype. Parkes, M. Genetic insights into common pathways and complex relationships among immune-mediated diseases. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis.

Psoriatic Arthritis. Ananthakrishnan, R. On the genetics of psoriasis. Brandrup, F. Psoriasis in monozygotic twins: variations in expression in individuals with identical genetic constitution.

Acta Derm. Lonnberg, A. Heritability of psoriasis in a large twin sample. Myers, A. Recurrence risk for psoriasis and psoriatic arthritis within sibships.

Rheumatology 44 , — Familial aggregation of psoriatic arthritis. Karason, A. A strong heritability of psoriatic arthritis over four generations — the Reykjavik Psoriatic Arthritis Study. Rheumatology 48 , — Winchester, R. HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype.

Eder, L. What have we learned about genetic susceptibility in psoriasis and psoriatic arthritis? Human leukocyte antigen alleles and susceptibility to psoriatic arthritis. Human leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasis. HLA-C locus alleles may modulate the clinical expression of psoriatic arthritis. FitzGerald, O. Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype.

Tang, H. A large-scale screen for coding variants predisposing to psoriasis. Ellinghaus, E. Cargill, M. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Liu, Y. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet. Huffmeier, U. Genome-wide meta-analysis of psoriatic arthritis identifies susceptibility locus at REL. Stuart, P. Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture.

Lanier, L. NK cell recognition. Killer-cell immunoglobulin-like receptor gene polymorphisms and susceptibility to psoriatic arthritis. Rheumatology 53 , — Weisman, M. The prevalence of inflammatory back pain: population-based estimates from the US National Health and Nutrition Examination Survey, — Mease, P. Development of criteria to distinguish inflammatory from noninflammatory arthritis, enthesitis, dactylitis, and spondylitis: a report from the GRAPPA annual meeting. Clinical expression, but not disease outcome, may vary according to age at disease onset in psoriatic spondylitis.

Joint Bone Spine 75 , — Helliwell, P. When symptoms are only present in peripheral joints, AS can be more challenging to diagnose. There is no single test that a doctor can use to check for PsA or AS. Instead, they must use a combination of the following techniques:. For AS, the deciding factor is often the condition of the sacroiliac joints. However, AS may not affect the area until the condition has been present for 10 years, so other tests are necessary.

There is currently no cure for either PsA or AS. However, there are various ways to reduce the symptoms, maximize flexibility, maintain posture, and limit complications. Effective treatments also slow down the progression of both conditions.

Individual treatment plans vary slightly, depending on the person and the severity of the condition. The following types of drugs may benefit people with spondyloarthritis, a type of disease that includes PsA and AS:. People with severe PsA or AS may need to undergo surgery. Hip joint replacement is a common surgical procedure for people with spondyloarthritis. If a person has a severely downward-curving spine, posture correction surgery can help, though the risks of this type of procedure are high.

PsA and AS are two types of spondyloarthritis. They cause chronic swelling, pain, and tenderness in and around the joints. Both PsA and AS can be challenging to diagnose, and neither condition is currently curable.

However, therapies can ease symptoms and improve the quality of life. Research into new treatment options is ongoing. Psoriasis seems to have a genetic component, and it can run in families. However, genetic features are not the only risk factor, as environmental…. There are five main types of psoriatic arthritis PsA. Learn the differences between them, how they present, treatments, and management. Regular exercise can help people manage the symptoms and progression of ankylosing spondylitis.

Here, learn about the best exercises, how to do them…. Some people have found that certain foods can worsen symptoms of psoriasis.